| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424476000 | Containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof (e.g., chocolate) | 10 |
| 20090252794 | TABLET - The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge. | 10-08-2009 |
| 20090274757 | PHARMACEUTICAL POLISH FORMULATIONS - Polish compositions for coating pharmaceutical solid dosage forms such as tablets are disclosed. The polish composition comprises water, coating agent, and a film forming agent. Polished pharmaceutical solid dosage forms such as tablets comprising a polished exterior surface are also disclosed. Processes of polishing pharmaceutical solid dosage forms such as tablets are disclosed. | 11-05-2009 |
| 20100068274 | PROCESS FOR PRODUCTION OF TABLET - An object of the present invention is to provide a dry coating method which can coat a tablet in a simple manner and with high efficiency, and therefore can produce a tablet having good appearance and hardly causing breaking/cracking. The present invention provides a process for producing a tablet coated with a coating agent comprising a meltable substance, comprising the steps of: heating a plain tablet to a temperature equal to or higher than a melting point of the meltable substance; and contacting the plain tablet with the coating agent to coat the plain tablet. | 03-18-2010 |
| 20100074951 | CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS - Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body. | 03-25-2010 |
| 20100203134 | SPHEROIDS AND MULTIPARTICULATE TABLETS COMPRISING THEM - The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of which include at least 8 carbon atoms; and (iii) an outer water-dispersible layer containing at least one disintegrating agent. The invention further relates to multiparticular tablets comprising said spheroids. | 08-12-2010 |
| 20110280942 | FILM COATING COMPOSITION AND METHODS OF MAKING AND USING THE SAME - A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to produce a film coating suspension. The film coating suspension can be applied to a substrate, such as a nutritional supplement, pharmaceutical, tablet, capsule, softgel, granule, particle, food confectionary form, agricultural seed, and the like to form a film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided. | 11-17-2011 |
| 20130122092 | THREE-PHASE CONTROLLED-RELEASE TABLET COMPRISING MELATONIN AND PROCESS OF PREPARATION - The invention relates, in one aspect, to a tablet having an internal core and external coating, both comprising melatonin and separated by an internal coating which does not comprise melatonin. The tablet is useful as a medicinal product, dietetic or food supplements for the treatment or as adjunctive therapy in sleep disorders. | 05-16-2013 |
| 20140154318 | LOTION TABLET THAT PROVIDES OXYGEN - There is provided a lotion tablet for the delivery of oxygen having an outer layer or “crust” coating an interior, that liberates oxygen upon rupture of the crust. The oxygen may be generated in the interior upon rupture of the crust or may be pre-formed or dissolved in the interior prior to coating the interior with the crust. The tablet would be easy to carry in airplanes, for example, making it readily available to the customer. Furthermore, the consumer may peel/tear open as many tablets as they desire, according to their needs/preference. | 06-05-2014 |
| 20150328166 | Device for the Treatment of Bone Conditions - A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions. | 11-19-2015 |
| 20160058709 | PLURIMODAL RELEASE FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND/OR METABOLITES OR SALTS THEREOF - A solid oral dosage form comprising a core comprising a doxylamine component and a pyridoxine component coated with an enteric coating is disclosed. The solid oral dosage form further comprises two active ingredient-containing coatings surrounding the enteric coating, the active ingredient-containing coatings being separated from one another by an intermediate coating, and one of the two active ingredient-containing coatings comprising a doxylamine component and being free of a pyridoxine component, and the other of the two active ingredient-containing coatings comprising a pyridoxine component and being free of doxylamine component. Uses of the solid oral dosage form for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP), are also disclosed. | 03-03-2016 |
